Since 2008, Cohen has served as president of CLC Consulting, a pharmaceutical and biotechnology consulting firm specializing in new product start-up and commercialization.
Prior to CLC, Cohen served as chief commercial officer of Medivation, Inc., a publicly-traded bio-pharmaceutical company, from September 2011 until July 2014.
From November 2007 to September 2008, she served as the vice president, strategic commercial group, of Health Care Systems, Inc., a Johnson and Johnson company, and from October 1998 to November 2007, she worked at Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.), a Johnson and Johnson company, in a variety of senior sales roles including vice president, rheumatology franchise.
In addition, Cohen served on the board of Aerpio Pharmaceuticals, Inc., a pharmaceutical company, since 2018 and also served on the board of Vital Therapies, Inc., a therapeutics company, from 2015 until 2019.
Since 2015, Cohen has served on the board of Novus Therapeutics, Inc. (reverse merger of Tokai Pharmaceuticals, Inc.), a publicly-traded pharmaceutical company focused on the acquisition, development, and commercialisation of ear, nose, and throat products and served on the board of Protein Sciences Corp., a privately held bio-pharmaceutical company specialising in vaccine development from October 2014 to August 2017.
She served on the board of Cytrx Corp., a bio-pharmaceutical company specialising in oncology, from June 2015 through October 2016.
Cohen began her career at Solvay Pharmaceuticals in a variety of sales positions and received her B.A. from Saint Joseph College.
NantKwest, a member of the NantWorks ecosystem of companies, is an innovative clinical-stage immunotherapy company.
NantKwest is positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care.
Natural Killer cells are a safeguard in the human body designed to recognise and detect cells under stress due to cancer or viral infection. NantKwest's "off-the-shelf" activated NK cell platform is designed to destroy cancer and virally infected cells from the body.
The safety of our NK cells as well as their activity against a range of cancers have been tested in phase I clinical trials in Canada and Europe as well as in multiple phase I and II clinical trials in the United States.
In addition to being a universal cell-based therapy that does not require individualised patient sourcing or matching, its NK cell products have been largely administered in the outpatient setting as an "off-the-shelf" living drug.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV